Clinical trial · Observational
Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)
UK Utility Study in Diffuse Large B-Cell Lymphoma
NCT02708732CI-TRIAL-00027095completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a prospective, cross-sectional survey to be administered to real patients in remission from DLBCL using a 15-minute postal or online survey. The project is designed to describe the impact of DLBCL remission on health utility and quality of life. Data collection will occur over a 4-month period.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- DLBCL Participants
- description
- A cohort of approximately 100 patients in first remission with DLBCL will complete questionnaires through a 15-minute postal or online survey.
Primary outcomes (1)
- measure
- Health-Related Quality of Life According to European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Score
- timeFrame
- Up to 4 months of data collection
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults greater than or equal to (\>/=) 18 years of age * Diagnosis of DLBCL and currently in first remission * Prior drug treatment for DLBCL Exclusion Criteria: * Receiving active treatment for DLBCL * Relapsed following any treatment for DLBCL
References
Publications (0)
Data not yet available
No reference posted for this study.